---
id: burkholderia-cepacia-complex_068
category: organisms
tags: [burkholderia-cepacia, cystic-fibrosis, TMP-SMX, ceftazidime, meropenem, MDR]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Burkholderia cepacia Complex (Bcc)

**Q:** What are the clinical features, treatment challenges (especially in cystic fibrosis), and management of B. cepacia complex infections?

**A:**

**Microbiology:**
- **Gram-negative bacillus** (aerobic, non-fermenter)
- **B. cepacia complex (Bcc):** ≥20 closely related species (genomovars)
  - Most clinically relevant: B. cenocepacia, B. multivorans, B. vietnamiensis
- **Intrinsically resistant** to many antibiotics
- Environmental organism (soil, water, plants, disinfectants)
- Biofilm producer

**Intrinsic Resistance:**
- **Aminoglycosides** (efflux, target modification)
- **Polymyxins** (colistin)
- **Many β-lactams** (AmpC β-lactamase)

---

**Epidemiology & Risk Factors:**

**Primary At-Risk Population:**
- **Cystic fibrosis (CF) patients** (10-20% colonized/infected)
- Chronic granulomatous disease (CGD)
- Immunocompromised (transplant, malignancy)
- Hospitalized patients (VAP, CLABSI, CAUTI)

**CF-Specific Concerns:**
- **Person-to-person transmission** (epidemic strains, e.g., ET12, PHDC)
- **"Cepacia syndrome":** Rapid necrotizing pneumonia, bacteremia, death (10-20% of CF patients with Bcc)
- **Contraindication to lung transplant** (relative) - high post-transplant mortality
- **Social isolation** (infection control - separate from other CF patients)

---

**Clinical Syndromes:**

**1. Cystic Fibrosis Lung Infection:**

**Chronic Colonization:**
- Gradual decline in lung function
- May be stable for years

**Acute Exacerbation:**
- ↑ Cough, sputum production
- ↓ FEV1, ↑ dyspnea
- Fever, weight loss

**"Cepacia Syndrome" (10-20% of CF patients with Bcc):**
- **Rapid necrotizing pneumonia**
- **Bacteremia**
- **High fever, leukocytosis**
- **Rapid clinical deterioration**
- **Mortality: >50%**

**Prognostic Factors (CF):**
- **B. cenocepacia** (especially genomovar III, ET12 lineage) → worse prognosis
- **B. multivorans** → better prognosis (more indolent)

**2. Non-CF Infections:**

**Hospital-Acquired:**
- VAP, CLABSI, CAUTI, wound infections
- Often in ICU patients with broad-spectrum antibiotic exposure

**Chronic Granulomatous Disease (CGD):**
- Pneumonia, lymphadenitis, osteomyelitis, liver abscesses
- High mortality

**Bacteremia:**
- Often catheter-associated
- Mortality 20-40%

---

**Diagnosis:**

**Culture:**
- Routine media (may require prolonged incubation)
- Selective media: **BCSA (Burkholderia cepacia selective agar)**, **OFPBL agar**
- Oxidase-positive (distinguishes from Stenotrophomonas)

**Species Identification:**
- **PCR, MALDI-TOF** (species-level identification important for prognosis in CF)

**Susceptibility Testing:**
- **Essential** (resistance varies between species and strains)
- No standardized breakpoints for some agents (use specialized labs)

---

**Treatment:**

**Key Challenges:**
- **Intrinsically multidrug-resistant**
- **Resistance varies by species** (B. cenocepacia more resistant than B. multivorans)
- **CF patients:** More resistant isolates (prior antibiotic exposure)
- **Limited clinical trial data**

**1. First-Line Antibiotics:**

**Commonly Active Agents:**

| **Antibiotic** | **Dosing** | **Susceptibility** | **Notes** |
|----------------|------------|-------------------|-----------|
| **TMP-SMX** | 5 mg/kg (TMP) IV q6-8h | 60-90% (CF: 60%) | First-line option |
| **Ceftazidime** | 2g IV q8h | 60-80% | First-line β-lactam |
| **Meropenem** | 1-2g IV q8h | 70-90% | Preferred carbapenem |
| **Minocycline** | 100 mg IV/PO q12h | 70-90% | Good alternative |
| **Chloramphenicol** | 50-100 mg/kg/day IV divided q6h | ~80% | Rarely used (toxicity) |

**Second-Line/Newer Agents:**

| **Antibiotic** | **Dosing** | **Notes** |
|----------------|------------|-----------|
| **Ceftazidime-avibactam** | 2.5g IV q8h | Some activity (limited data) |
| **Cefiderocol** | 2g IV q8h (3h infusion) | Activity against Bcc (emerging data) |

**Antibiotics with POOR Activity:**
- **Aminoglycosides** (intrinsically resistant)
- **Polymyxins** (colistin - intrinsically resistant)
- **Aztreonam** (variable, often resistant)
- **Fluoroquinolones** (variable, often resistant)

---

**2. Treatment Strategies:**

**Combination vs Monotherapy:**
- **Combination therapy preferred** (especially for severe infections, CF exacerbations)
- Rationale: Synergy, prevent resistance emergence

**Common Combinations:**
- **TMP-SMX + ceftazidime**
- **Meropenem + minocycline**
- **TMP-SMX + meropenem**
- **Ceftazidime + minocycline**

**Duration:**
- **Non-CF infections:** 14-21 days
- **CF pulmonary exacerbation:** 14-21 days (or longer if needed)
- **Bacteremia:** ≥14 days (longer if complicated)

**3. CF-Specific Considerations:**

**Acute Exacerbation:**
- IV combination therapy (TMP-SMX + ceftazidime OR meropenem-based)
- Duration: 14-21 days
- Monitor FEV1 response

**Eradication Protocols (Early Infection):**
- **Goal:** Eradicate before chronic colonization established
- Regimen: **Inhaled tobramycin + oral TMP-SMX** (or inhaled amiloride + tobramycin + TMP-SMX)
- Success rates: 30-60% (difficult to achieve)

**Chronic Suppressive Therapy:**
- Controversial (no clear benefit, promotes resistance)
- Consider oral TMP-SMX for frequent exacerbations

**Cepacia Syndrome:**
- **ICU-level care**
- IV combination therapy (≥2 active agents)
- Mortality >50% despite treatment

---

**Resistance Patterns:**

**TMP-SMX Resistance:**
- 10-40% in CF patients (↑ with prior exposure)
- 0-20% in non-CF patients

**Ceftazidime Resistance:**
- Variable (20-40% in CF)

**High-Level Resistance (XDR Bcc):**
- Emerging problem in CF
- Resistance to TMP-SMX, ceftazidime, meropenem, minocycline
- Consider cefiderocol, ceftazidime-avibactam (limited data)

---

**Infection Control (CF Patients):**

**Segregation Policies:**
- **Bcc-positive CF patients segregated** from Bcc-negative patients
- Person-to-person transmission documented (epidemic strains)
- Separate clinic days, inpatient rooms

**Lung Transplant Considerations:**
- **B. cenocepacia:** Relative contraindication (high post-transplant mortality)
- **B. multivorans:** Not absolute contraindication (lower risk)
- Decision based on species, transplant center policies

---

**Prognosis:**

**CF Patients:**
- **Without Bcc:** Median survival ~40 years
- **With Bcc (B. multivorans):** Modestly ↓ survival
- **With B. cenocepacia:** Significantly ↓ survival (especially genomovar III)
- **Cepacia syndrome:** >50% mortality

**Non-CF Patients:**
- Bacteremia mortality: 20-40%
- VAP mortality: 30-50%

---

**Comparison: B. cepacia Complex vs B. pseudomallei**

| **Feature** | **B. cepacia complex** | **B. pseudomallei** |
|-------------|------------------------|---------------------|
| **Primary risk** | **Cystic fibrosis** | **Endemic areas** (SE Asia, N Australia) |
| **Geography** | Worldwide | Tropical (endemic zones) |
| **Intrinsic resistance** | Aminoglycosides, polymyxins | Aminoglycosides, polymyxins, many β-lactams |
| **First-line Rx** | **TMP-SMX, ceftazidime, meropenem** | **Ceftazidime or meropenem** (acute), **TMP-SMX** (eradication) |
| **Person-to-person** | ✅ Yes (CF patients) | ❌ No |
| **Mortality (CF)** | Cepacia syndrome >50% | N/A |

---

**Mnemonic: "Bcc = Burkholderia causes Cystic fibrosis complications, choose combination (TMP-SMX + ceftazidime)"**
- **B**urkholderia cepacia complex
- **C**ystic fibrosis (#1 risk)
- **C**ombination therapy preferred

**Mnemonic: "CF + Bcc = Catastrophic (Cepacia syndrome)"**
- **C**epacia syndrome (10-20%)
- **F**ulminant necrotizing pneumonia
- **B**acteremia
- **C**ontraindication to transplant (relative)

**Clinical Pearls:**
- **Bcc = CF pathogen** (10-20% of CF patients)
- **Intrinsically resistant** to aminoglycosides, polymyxins
- **TMP-SMX + ceftazidime** common first-line combination
- **B. cenocepacia (genomovar III)** → worst prognosis (Cepacia syndrome, ↑ mortality)
- **B. multivorans** → better prognosis (more indolent)
- **Person-to-person transmission** in CF → segregation policies
- **Cepacia syndrome:** Fulminant necrotizing pneumonia + bacteremia (>50% mortality)
- **Lung transplant:** B. cenocepacia = relative contraindication (high post-transplant mortality)
- **Eradication difficult** (biofilm, intrinsic resistance)
- **CF patients have more resistant isolates** (10-40% TMP-SMX resistance)
- Avoid **aminoglycosides and polymyxins** (intrinsically resistant)
- **Combination therapy preferred** (especially severe infections)
- **Chloramphenicol active** but rarely used (bone marrow toxicity)

**Media:** None

**Sources:** [PubMed 2024 - Bcc in CF critical gaps], [Medscape 2024 - B. cepacia medication], [Taylor & Francis 2024 - Bcc in CF], [PMC 2018 - Successful eradication protocol], [PMC 2017 - CAZ-AVI for persistent Bcc bacteremia], [PubMed 2015 - Clinical and in vitro evidence], [Frontiers 2024 - Phage therapy for CF Bcc], [Cochrane 2012 - Antibiotic treatment for Bcc in CF exacerbation]
